Fractional flow reserve tests, which assess arterial pressure as a way to evaluate the effects of blockage, have offered physicians a more precise way to determine which patients are good candidates for stenting. That helps ensure they get optimal treatment when they need it, according to SCAI secretary Dr. James Blankenship, keeping quality high and costs relatively low. The market for FFR tests was forecast to reach $200 million in 2012 and could grow rapidly if the technology is found to have similar success in arteries in other parts of the body.

Full Story:

Related Summaries